OverviewSuggest Edit
Novartis is a company that researches, develops, manufactures, and markets healthcare products. It comprises 2 global operation divisions: Innovative Medicines and Sandoz. The Innovative Medicines division offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz division provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory.
| Type | Public | |
| Founded | 1996 | |
| HQ | Basel, CH | Map |
| Website | novartis.com | |
| Employee Ratings | More |
Recent NewsAll News
- Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)
- AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy
- New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines
- Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
Key People/Management at Novartis
Vasant Narasimhan
Chief Executive Officer
Joerg Reinhardt
Chairman
Bertrand Bodson
Chief Digital Officer
Steven Baert
Chief People & Organization Officer
James Bradner
President of the Novartis Institutes for BioMedical Research (NIBR)
Harry Kirsch
Chief Financial Officer
Novartis Office Locations
Novartis has offices in Basel, Schweizerhalle, Stein, Broomfield and in 164 other locations
Basel, CH (HQ)
Fabrikstrasse 2
Basel, CH
210, Lichtstrasse 35
Schweizerhalle, CH
Rothausstrasse 61
Stein, CH
Schaffhauserstrasse
Tirana, AL
Rruga Hoxha Tahsim 23
Bir Mourad Raïs, DZ
Said Hamdine
Novartis Financials and Metrics
Novartis Revenue
Novartis's revenue was reported to be $47.45 b in FY, 2019 which is a 8.6% decrease from the previous period.
| USD | |
|---|---|
Revenue (Q3, 2020) | 12.3b |
Gross profit (Q3, 2020) | 8.5b |
Gross profit margin (Q3, 2020), % | 69.4% |
Net income (Q3, 2020) | 1.9b |
EBIT (Q3, 2020) | 2.4b |
Market capitalization (15-Jan-2021) | 194.0b |
Closing stock price (15-Jan-2021) | 85.3 |
Cash (30-Sept-2020) | 9.0b |
EV | 223.2b |
Novartis's current market capitalization is CHF194 b.
- Source: Company Filings
Annual
- Source: Company Filings
Annual
- Source: Company Filings
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 2.0b | 9.8b | 11.4b | 1.9b | 4.0b | 6.0b | 2.2b | 4.0b | 6.0b |
Depreciation and Amortization | 4.9b | 1.4b | 2.5b | 3.9b | 1.4b | 3.1b | |||
Cash From Operating Activities | 2.5b | 6.5b | 10.5b | 2.4b | 5.5b | 10.1b | 2.5b | 6.5b | 9.6b |
Purchases of PP&E | (359.0m) | (690.0m) | (1.1b) | (282.0m) | (561.0m) | (918.0m) | (237.0m) | (475.0m) | (754.0m) |
- Source: Company Filings
| USD | FY, 2017 |
|---|---|
EV/EBIT | 22.6 x |
EV/CFO | 15.5 x |
Revenue/Employee | 403.9k |
Debt/Equity | 0.4 x |
Debt/Assets | 0.2 x |
Financial Leverage | 1.8 x |
P/E Ratio | 22.2 |
Novartis Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Vedere Bio | October 29, 2020 | $280 m |
| Amblyotech | April 21, 2020 | |
| The Medicines Company | November 25, 2019 | $9.70 b |
| Xiidra | May 09, 2019 | $1.90 b |
| Novartis Inflammasome Research | April 02, 2019 | $1.58 b |
| CellforCure | December 21, 2018 | |
| Endocyte | October 18, 2018 | |
| AveXis | April 09, 2018 | $8.70 b |
| Advanced Accelerator Applications | October 30, 2017 | $3.90 b |
| Encore Vision | December 20, 2016 |
Novartis Revenue Breakdown
Novartis revenue breakdown by business segment: 20.5% from Sandoz and 79.5% from Innovative Medicines
Novartis revenue breakdown by geographic segment: 5.6% from Japan , 34.3% from United States, 5.1% from France, 8.7% from Germany and 46.3% from Other
Novartis Cybersecurity Score
Novartis Environment, Social & Governance (ESG) Ratings
Novartis Online and Social Media Presence
284.7k Twitter followers
Novartis has 284.7k Twitter Followers. The number of followers has increased 0.6% month over month and increased 2% quarter over quarter
Novartis's Trends
Twitter Engagement Stats for @novartis
12.4k
Tweets
569
Following
284.7k
Followers
17
Tweets last 30 days
1.4
Avg. likes per Tweet
29.4%
Tweets with engagement
Novartis News and Updates
September 02, 2021
AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy
Novartis has renamed the previously acquired AveXis to Novartis Gene Therapies.
September 01, 2021
New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines
Novartis and the African Union (AU) through the Africa Medical Supplies Platform (AMSP) have announced a new collaboration to facilitate the supply of medicines from the Novartis Pandemic Response Portfolio to the AU member states and Caricom countries.
January 14, 2021
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1 Currently there are limited approved therapies for patients with CSU, also known as chronic…
January 14, 2021
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted ligelizumab (QGE031) Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-an…
January 12, 2021
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth Novartis secures development and commercialization rights in North America, Europe, and Japan …
Novartis Frequently Asked Questions
When was Novartis founded?
Novartis was founded in 1996.
Who are Novartis key executives?
Novartis's key executives are Vasant Narasimhan, Joerg Reinhardt and Bertrand Bodson.
How many employees does Novartis have?
Novartis has 103,914 employees.
What is Novartis revenue?
Latest Novartis annual revenue is $47.4 b.
What is Novartis revenue per employee?
Latest Novartis revenue per employee is $456.6 k.
Who are Novartis competitors?
Competitors of Novartis include Bausch + Lomb, Immunomedics and Gilead Sciences.
Where is Novartis headquarters?
Novartis headquarters is located at Fabrikstrasse 2, Basel.
Where are Novartis offices?
Novartis has offices in Basel, Schweizerhalle, Stein, Broomfield and in 164 other locations.
How many offices does Novartis have?
Novartis has 181 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies